Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.
Identifieur interne : 001242 ( Main/Curation ); précédent : 001241; suivant : 001243Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.
Auteurs : A C Del Re [États-Unis] ; Natalya Maisel ; Janet C. Blodgett ; Paula Wilbourne ; John W. FinneySource :
- Journal of clinical psychopharmacology [ 1533-712X ] ; 2013.
Descripteurs français
- KwdFr :
- Analyse multifactorielle (MeSH), Effet placebo (MeSH), Essais cliniques contrôlés comme sujet (méthodes), Essais cliniques contrôlés comme sujet (tendances), Facteurs temps (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Plan de recherche (tendances), Résultat thérapeutique (MeSH), Troubles liés à l'alcool (diagnostic), Troubles liés à l'alcool (traitement médicamenteux).
- MESH :
- diagnostic : Troubles liés à l'alcool.
- méthodes : Essais cliniques contrôlés comme sujet.
- tendances : Essais cliniques contrôlés comme sujet, Plan de recherche.
- traitement médicamenteux : Troubles liés à l'alcool.
- Analyse multifactorielle, Effet placebo, Facteurs temps, Humains, Indice de gravité de la maladie, Résultat thérapeutique.
English descriptors
- KwdEn :
- Alcohol-Related Disorders (diagnosis), Alcohol-Related Disorders (drug therapy), Controlled Clinical Trials as Topic (methods), Controlled Clinical Trials as Topic (trends), Humans (MeSH), Multivariate Analysis (MeSH), Placebo Effect (MeSH), Research Design (trends), Severity of Illness Index (MeSH), Time Factors (MeSH), Treatment Outcome (MeSH).
- MESH :
- diagnosis : Alcohol-Related Disorders.
- drug therapy : Alcohol-Related Disorders.
- methods : Controlled Clinical Trials as Topic.
- trends : Controlled Clinical Trials as Topic, Research Design.
- Humans, Multivariate Analysis, Placebo Effect, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
OBJECTIVE
Placebo group improvement in pharmacotherapy trials has been increasing over time across several pharmacological treatment areas. However, it is unknown to what degree increasing improvement has occurred in pharmacotherapy trials for alcohol use disorders or what factors may account for placebo group improvement. This meta-analysis of 47 alcohol pharmacotherapy trials evaluated (1) the magnitude of placebo group improvement, (2) the extent to which placebo group improvement has been increasing over time, and (3) several potential moderators that might account for variation in placebo group improvement.
METHOD
Random-effects univariate and multivariate analyses were conducted that examined the magnitude of placebo group improvement in the 47 studies and several potential moderators of improvement: (a) publication year, (b) country in which the study was conducted, (c) outcome data source/type, (d) number of placebo administrations, (e) overall severity of study participants, and (f) additional psychosocial treatment.
RESULTS
Substantial placebo group improvement was found overall and improvement was larger in more recent studies. Greater improvement was found on moderately subjective outcomes, with more frequent administrations of the placebo, and in studies with greater participant severity of illness. However, even after controlling for these moderators, placebo group improvement remained significant, as did placebo group improvement over time.
CONCLUSIONS
Similar to previous pharmacotherapy placebo research, substantial pretest to posttest placebo group improvement has occurred in alcohol pharmacotherapy trials, an effect that has been increasing over time. However, several plausible moderator variables were not able to explain why placebo group improvement has been increasing over time.
DOI: 10.1097/JCP.0b013e3182983e73
PubMed: 23857312
PubMed Central: PMC4076955
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001242
Links to Exploration step
pubmed:23857312Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.</title><author><name sortKey="Del Re, A C" sort="Del Re, A C" uniqKey="Del Re A" first="A C" last="Del Re">A C Del Re</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Care Evaluation, Stanford University Medical School, VA Palo Alto Health Care System, 152MPD, 795 Willow Rd, Menlo Park, CA 94025, USA. acdelre@stanford.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Health Care Evaluation, Stanford University Medical School, VA Palo Alto Health Care System, 152MPD, 795 Willow Rd, Menlo Park, CA 94025</wicri:regionArea></affiliation></author><author><name sortKey="Maisel, Natalya" sort="Maisel, Natalya" uniqKey="Maisel N" first="Natalya" last="Maisel">Natalya Maisel</name></author><author><name sortKey="Blodgett, Janet C" sort="Blodgett, Janet C" uniqKey="Blodgett J" first="Janet C" last="Blodgett">Janet C. Blodgett</name></author><author><name sortKey="Wilbourne, Paula" sort="Wilbourne, Paula" uniqKey="Wilbourne P" first="Paula" last="Wilbourne">Paula Wilbourne</name></author><author><name sortKey="Finney, John W" sort="Finney, John W" uniqKey="Finney J" first="John W" last="Finney">John W. Finney</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23857312</idno><idno type="pmid">23857312</idno><idno type="doi">10.1097/JCP.0b013e3182983e73</idno><idno type="pmc">PMC4076955</idno><idno type="wicri:Area/Main/Corpus">001242</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001242</idno><idno type="wicri:Area/Main/Curation">001242</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001242</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.</title><author><name sortKey="Del Re, A C" sort="Del Re, A C" uniqKey="Del Re A" first="A C" last="Del Re">A C Del Re</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Care Evaluation, Stanford University Medical School, VA Palo Alto Health Care System, 152MPD, 795 Willow Rd, Menlo Park, CA 94025, USA. acdelre@stanford.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Health Care Evaluation, Stanford University Medical School, VA Palo Alto Health Care System, 152MPD, 795 Willow Rd, Menlo Park, CA 94025</wicri:regionArea></affiliation></author><author><name sortKey="Maisel, Natalya" sort="Maisel, Natalya" uniqKey="Maisel N" first="Natalya" last="Maisel">Natalya Maisel</name></author><author><name sortKey="Blodgett, Janet C" sort="Blodgett, Janet C" uniqKey="Blodgett J" first="Janet C" last="Blodgett">Janet C. Blodgett</name></author><author><name sortKey="Wilbourne, Paula" sort="Wilbourne, Paula" uniqKey="Wilbourne P" first="Paula" last="Wilbourne">Paula Wilbourne</name></author><author><name sortKey="Finney, John W" sort="Finney, John W" uniqKey="Finney J" first="John W" last="Finney">John W. Finney</name></author></analytic><series><title level="j">Journal of clinical psychopharmacology</title><idno type="eISSN">1533-712X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alcohol-Related Disorders (diagnosis)</term><term>Alcohol-Related Disorders (drug therapy)</term><term>Controlled Clinical Trials as Topic (methods)</term><term>Controlled Clinical Trials as Topic (trends)</term><term>Humans (MeSH)</term><term>Multivariate Analysis (MeSH)</term><term>Placebo Effect (MeSH)</term><term>Research Design (trends)</term><term>Severity of Illness Index (MeSH)</term><term>Time Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse multifactorielle (MeSH)</term><term>Effet placebo (MeSH)</term><term>Essais cliniques contrôlés comme sujet (méthodes)</term><term>Essais cliniques contrôlés comme sujet (tendances)</term><term>Facteurs temps (MeSH)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Plan de recherche (tendances)</term><term>Résultat thérapeutique (MeSH)</term><term>Troubles liés à l'alcool (diagnostic)</term><term>Troubles liés à l'alcool (traitement médicamenteux)</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Alcohol-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Troubles liés à l'alcool</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alcohol-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Controlled Clinical Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais cliniques contrôlés comme sujet</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Essais cliniques contrôlés comme sujet</term><term>Plan de recherche</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Troubles liés à l'alcool</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Controlled Clinical Trials as Topic</term><term>Research Design</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Multivariate Analysis</term><term>Placebo Effect</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse multifactorielle</term><term>Effet placebo</term><term>Facteurs temps</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>Placebo group improvement in pharmacotherapy trials has been increasing over time across several pharmacological treatment areas. However, it is unknown to what degree increasing improvement has occurred in pharmacotherapy trials for alcohol use disorders or what factors may account for placebo group improvement. This meta-analysis of 47 alcohol pharmacotherapy trials evaluated (1) the magnitude of placebo group improvement, (2) the extent to which placebo group improvement has been increasing over time, and (3) several potential moderators that might account for variation in placebo group improvement.</p></div><div type="abstract" xml:lang="en"><p><b>METHOD</b></p><p>Random-effects univariate and multivariate analyses were conducted that examined the magnitude of placebo group improvement in the 47 studies and several potential moderators of improvement: (a) publication year, (b) country in which the study was conducted, (c) outcome data source/type, (d) number of placebo administrations, (e) overall severity of study participants, and (f) additional psychosocial treatment.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Substantial placebo group improvement was found overall and improvement was larger in more recent studies. Greater improvement was found on moderately subjective outcomes, with more frequent administrations of the placebo, and in studies with greater participant severity of illness. However, even after controlling for these moderators, placebo group improvement remained significant, as did placebo group improvement over time.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Similar to previous pharmacotherapy placebo research, substantial pretest to posttest placebo group improvement has occurred in alcohol pharmacotherapy trials, an effect that has been increasing over time. However, several plausible moderator variables were not able to explain why placebo group improvement has been increasing over time.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23857312</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.</ArticleTitle><Pagination><MedlinePgn>649-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0b013e3182983e73</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Placebo group improvement in pharmacotherapy trials has been increasing over time across several pharmacological treatment areas. However, it is unknown to what degree increasing improvement has occurred in pharmacotherapy trials for alcohol use disorders or what factors may account for placebo group improvement. This meta-analysis of 47 alcohol pharmacotherapy trials evaluated (1) the magnitude of placebo group improvement, (2) the extent to which placebo group improvement has been increasing over time, and (3) several potential moderators that might account for variation in placebo group improvement.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Random-effects univariate and multivariate analyses were conducted that examined the magnitude of placebo group improvement in the 47 studies and several potential moderators of improvement: (a) publication year, (b) country in which the study was conducted, (c) outcome data source/type, (d) number of placebo administrations, (e) overall severity of study participants, and (f) additional psychosocial treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Substantial placebo group improvement was found overall and improvement was larger in more recent studies. Greater improvement was found on moderately subjective outcomes, with more frequent administrations of the placebo, and in studies with greater participant severity of illness. However, even after controlling for these moderators, placebo group improvement remained significant, as did placebo group improvement over time.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Similar to previous pharmacotherapy placebo research, substantial pretest to posttest placebo group improvement has occurred in alcohol pharmacotherapy trials, an effect that has been increasing over time. However, several plausible moderator variables were not able to explain why placebo group improvement has been increasing over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Re</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Center for Health Care Evaluation, Stanford University Medical School, VA Palo Alto Health Care System, 152MPD, 795 Willow Rd, Menlo Park, CA 94025, USA. acdelre@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maisel</LastName><ForeName>Natalya</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Blodgett</LastName><ForeName>Janet C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Wilbourne</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Finney</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AA008689</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AA008689</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019973" MajorTopicYN="N">Alcohol-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015990" MajorTopicYN="Y">Placebo Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23857312</ArticleId><ArticleId IdType="doi">10.1097/JCP.0b013e3182983e73</ArticleId><ArticleId IdType="pmc">PMC4076955</ArticleId><ArticleId IdType="mid">NIHMS581390</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychopharmacol. 2002 Dec;22(6):592-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12454559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2005 Aug;25(4):349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16012278</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2008 Jul;32(7):1299-308</Citation><ArticleIdList><ArticleId IdType="pubmed">18540910</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2002 Mar;97(3):265-77</Citation><ArticleIdList><ArticleId IdType="pubmed">11964100</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1998 Aug;22(5):1074-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9726277</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 1990;25(6):613-22</Citation><ArticleIdList><ArticleId IdType="pubmed">2085344</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2006 May 3;295(17):2003-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16670409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 May;69(5):701-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18312058</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Aug;54(8):737-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9283509</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2004 Mar;172(3):291-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14634716</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2008 Jul;32(7):1271-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18482155</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2002 Aug 30;21(16):2313-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12210616</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2005 Mar;29(3):395-401</Citation><ArticleIdList><ArticleId IdType="pubmed">15770115</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Apr 14;281(14):1318-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10208148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995;56 Suppl 7:39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">7673104</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2001 Nov;96(11):1565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11784454</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2004 Sep;28(9):1356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15365306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2000 Apr;20(2):129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10770449</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2009 Jan 1;99(1-3):317-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18644685</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Addict. 2009 Sep-Oct;18(5):356-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19874153</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 2003 Mar-Apr;38(2):135-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12634260</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2004 Jul;99(7):811-28</Citation><ArticleIdList><ArticleId IdType="pubmed">15200577</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1998 Sep;139(1-2):44-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9768541</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2003 Jul;27(7):1142-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12878920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2002 Mar 19;136(6):471-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11900500</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 May;36(3):504-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18723840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Dec 8;370(9603):1915-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18068515</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2009 Dec 11;1305 Suppl:S2-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19799882</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1996 Mar;53(3):232-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8611060</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 2002 Jun 3;176(11):530-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12064984</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2006 Oct;101(10):1451-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16968347</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2011 Sep 10;30(20):2481-98</Citation><ArticleIdList><ArticleId IdType="pubmed">21268052</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Oct;65(10):1406-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15491246</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Oct;165(4):515-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7804666</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1997 Dec;50(12):1311-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9449934</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2008 Jan;32(1):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18028530</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2011 Dec;31(8):1304-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21996291</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2008 Jan;103(1):42-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17999707</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2004 Mar;28(3):433-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15084901</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 May 24;344(21):1594-602</Citation><ArticleIdList><ArticleId IdType="pubmed">11372012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2007 Apr;63(4):401-3; discussion 405-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17279522</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 May 15;57(10):1128-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15866552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2003 Dec;23(6):553-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14624185</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2007 Apr;63(4):379-90; discussion 405-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17279527</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2010 Nov;16(11):1277-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20948533</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2000 May;22(5):493-503</Citation><ArticleIdList><ArticleId IdType="pubmed">10731624</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Nov;68(11):1691-700</Citation><ArticleIdList><ArticleId IdType="pubmed">18052562</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2002 Sep;26(9):1381-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12351933</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2008 Dec;103(12):2035-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18855810</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychotherapy (Chic). 2011 Mar;48(1):58-64</Citation><ArticleIdList><ArticleId IdType="pubmed">21401275</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2007 Oct 10;298(14):1641-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17925516</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2004 Nov;28(11):1710-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15547458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Subst Abuse Treat. 2008 Jun;34(4):378-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17664051</ArticleId></ArticleIdList></Reference><Reference><Citation>Prev Sci. 2000 Dec;1(4):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11523746</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Jun;31(6):1310-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16237394</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2006 May 3;295(17):2075-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16670416</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1972 Jun 10;1(7763):1279-82</Citation><ArticleIdList><ArticleId IdType="pubmed">4113531</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Addict. 2003 Jul-Sep;12(4):281-94</Citation><ArticleIdList><ArticleId IdType="pubmed">14504021</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2007 May;31(5):775-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychotherapy (Chic). 2011 Mar;48(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21401269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1985 May 4;1(8436):1014-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2859465</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Nov;156(11):1758-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10553740</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2004 Jul;28(7):1051-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15252291</ArticleId></ArticleIdList></Reference><Reference><Citation>J Couns Psychol. 2012 Jan;59(1):10-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21988681</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2005 Jun;29(6):983-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15976524</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2008 Jan;32(1):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18028529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010;(1):CD003974</Citation><ArticleIdList><ArticleId IdType="pubmed">20091554</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2001 Sep;25(9):1335-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11584154</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Nov;118(1-3):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19246102</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1954 Jun;16(6):770-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13158365</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jan;60(1):92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12511176</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 2000 Nov-Dec;35(6):587-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11093966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2005 Jul;61(7):835-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15827993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2007 Aug;27(4):344-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17632217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001242 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001242 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:23857312
|texte= Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:23857312" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |